25,659 Eli Lilly and Company $LLY Shares Sold by Public Sector Pension Investment Board

Eli Lilly and Company logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Public Sector Pension Investment Board cut its Eli Lilly stake by 7%, selling 25,659 shares in the third quarter and retaining 342,697 shares valued at about $397.5 million.
  • Analysts remain broadly positive: Lilly has a “Moderate Buy” consensus and an average price target of $1,422, with 24 analysts rating it Buy.
  • Lilly reported quarterly EPS of $7.48, beating the $5.71 consensus, while revenue rose 38.6% year over year to $24.4 billion.
  • Five stocks we like better than Eli Lilly and Company.

Public Sector Pension Investment Board lowered its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 7.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 342,697 shares of the company's stock after selling 25,659 shares during the period. Eli Lilly and Company makes up 0.9% of Public Sector Pension Investment Board's portfolio, making the stock its 17th biggest position. Public Sector Pension Investment Board's holdings in Eli Lilly and Company were worth $397,505,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the business. BlackRock Inc. raised its position in Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after buying an additional 1,046,558 shares during the period. State Street Corp lifted its stake in Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company's stock worth $43,438,262,000 after acquiring an additional 605,752 shares in the last quarter. Bank of America Corp DE purchased a new stake in Eli Lilly and Company in the 2nd quarter worth about $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Eli Lilly and Company by 1.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock worth $8,647,153,000 after acquiring an additional 137,364 shares during the period. Finally, Jennison Associates LLC boosted its position in Eli Lilly and Company by 7.9% during the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock worth $6,550,587,000 after acquiring an additional 400,538 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Ratings Changes

Several equities analysts have weighed in on LLY shares. UBS Group lifted their target price on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a "buy" rating in a research note on Friday, October 30th. HSBC increased their price target on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a "reduce" rating in a research report on Thursday, September 10th. Weiss Ratings upgraded shares of Eli Lilly and Company from a "buy (b)" rating to a "buy (b+)" rating in a report on Friday. Citigroup raised their price target on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a "buy" rating in a report on Friday, October 30th. Finally, Scotiabank boosted their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a "sector outperform" rating in a research report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average target price of $1,422.00.

Read Our Latest Research Report on LLY

Key Eli Lilly and Company News

Here's some of the latest news about LLY:

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,412.63 on Wednesday. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,475.25. The business has a fifty day simple moving average of $1,253.71 and a 200 day simple moving average of $1,114.28. The firm has a market cap of $1.33 trillion, a price-to-earnings ratio of 45.85, a P/E/G ratio of 1.71 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The firm had revenue of $24.40 billion during the quarter, compared to analysts' expectations of $22.58 billion. During the same quarter last year, the firm earned $7.02 earnings per share. The business's revenue for the quarter was up 38.6% on a year-over-year basis. As a group, sell-side analysts predict that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company's dividend payout ratio (DPR) is 22.46%.

Insider Activity

In other news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. The trade was a 54.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Eli Lilly and Company Right Now?

Before you consider Eli Lilly and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.

While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines